Dugan resigns from Acuson
Acuson of Mountain View, CA, announced that company president and director Daniel Dugan resigned effective March 1. Former Acuson president Robert Gallagher will come out of retirement to serve as president and chief operating officer until sometime in
Acuson of Mountain View, CA, announced that company president and director Daniel Dugan resigned effective March 1. Former Acuson president Robert Gallagher will come out of retirement to serve as president and chief operating officer until sometime in June, when a permanent replacement for Dugan will be named. Gallagher, 56, previously was president and chief operating officer.
Dugan, 45, has been with Acuson for many years. He held senior sales management positions with the company from 1984 to 1989, then returned in 1991 as vice president of field operations after spending two years at Toshiba America Medical Systems as vice president of U.S. ultrasound business operations. Dugan was made vice president of worldwide sales and field operations for Acuson in 1993, and senior vice president of worldwide sales, service, and marketing in March 1994. He was promoted to president in November 1997.
Dugans departure appears to be unrelated to the companys financial performance. In fact, the company is coming off its most successful year ever and record fourth-quarter revenues. The ultrasound vendor posted revenues of $135 million for the fourth quarter of 1999, an increase of 10% compared with the fourth quarter of 1998, and $475.9 million for the year, compared to $455 million in 1998. Excluding a one-time $13.9 million after-tax write-off associated with the December 1999 acquisition of Ecton, the company reported net income of $6.8 million in the fourth quarter of 1998. Including the write-off, Acuson reported a net loss for the quarter of $7.1 million.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
